SCHEMBL6933249

SCHEMBL6933249

CC(C)O[C@@H]1O[C@H](CCP(C)(C)=O)[C@@H](O)[C@H]1O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF2R P11717 7/20 0.43
PRKD3 O94806 1/20 0.37
PRKCG P05129 1/20 0.37
PRKCB P05771 1/20 0.37
PRKCA P17252 1/20 0.37
PRKCH P24723 1/20 0.37
PRKCI P41743 1/20 0.37
PRKCE Q02156 1/20 0.37
PRKCQ Q04759 1/20 0.37
PRKCZ Q05513 1/20 0.37
PRKCD Q05655 1/20 0.37
PRKD1 Q15139 1/20 0.37
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
TYR P14679 2/20 0.33
ALDH1A1 P00352 1/20 0.32
THRB P10828 1/20 0.32
FBP1 P09467 1/20 0.32
KDR P35968 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25083591 0.88 IGF2R (0.48) IGF2RPRKD3PRKCGPRKCBPRKCA
SCHEMBL25494488 0.86 IGF2R (0.59) IGF2RPRKD3PRKCGPRKCBPRKCA
SCHEMBL25495348 0.86 IGF2R (0.59) IGF2RPRKD3PRKCGPRKCBPRKCA
SCHEMBL10259213 0.85 IGF2R (0.42) IGF2RPRKD3PRKCGPRKCBPRKCA
SCHEMBL12958027 0.77
SCHEMBL6933251 0.75 CA1 (0.37) IGF2RPRKD3PRKCGPRKCBPRKCA
SCHEMBL25495343 0.75 IGF2R (0.58) IGF2RPRKD3PRKCGPRKCBPRKCA
SCHEMBL24943577 0.74 L3MBTL1 (0.49) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL10388282 0.74 L3MBTL1 (0.49) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL19770588 0.74 L3MBTL1 (0.49) PRKD3PRKCGPRKCBPRKCAPRKCH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9120774-B2 Novobiocin analogues having modified sugar moieties UNIVERSITY OF KANSAS (US) 2015-09-01 US disclosed
US-20120252745-A1 NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-10-04 US disclosed
US-20110082098-A1 NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE UNIVERSITY OF KANSAS (US) 2011-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252745-A1 NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES HSP90AB1, HSP90AB2P, HSP90B1 IGF2R 944/4885PRKD3 1729/4885PRKCG 2391/4885
US-20110082098-A1 NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE PKD1, PKD2, HSP90B1 IGF2R 3531/4885PRKD3 63/4885PRKCG 246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.